]>

Table 1: Clinical characteristics at baseline in type 2 diabetic patients.

Patients No. (male/female) 34 (12/22) Age (year) 63.1 ±9.1 Duration of diabetes (year) 13.0 ±6.8 BMI (kg/m2) 24.5 ±3.7 Diabetic therapy  Insulin 6  SU 19 (SU1/SU2/SU3/SU4/ 1/3/5/3/2/1/4 SU5/SU6/SU7)  Metformin (Met) 2  α-GI/α-GI, Met 1/3  Diet alone 3 Antihypertensive drugs 17 ARB/Ca/ACE-I/ARB, Ca/ 3/5/1/5/2/1 ACE, Ca/ARB, ACE-I, Ca  Statins 2

Data are expressed as mean $\pm$ standard deviation (SD). Comparisons in variables between two groups were made by use of an unpaired $t$ test. $P\text{:}$$P$ value, $P<.05$ are defined as statistical significance. BMI: body mass index; Diabetic therapy: the number of the patients with respective diabetic therapies; Insulin: insulin therapy; SU: sulfonylurea; $\alpha$-GI: $\alpha$ glucosidase inhibitor; SU1:SU alone; SU2: SU; $\alpha$-GI, SU3: SU, Met, SU4: SU, pioglitazone, SU5: SU, $\alpha$-GI, Met, SU6: SU, $\alpha$-GI, pioglitazone, SU7: SU, Met, pioglitazone and/or $\alpha$-GI: Antihypertensive drugs: the number of the patients with respective antihypertensive drugs; ARB: angiotensin-II receptor blocker; Ca: calcium channel blocker, ACE-I: angiotensin-I converting enzyme inhibitor.